← All stocks

Arcus Biosciences, Inc.

RCUS Scheduled selling only

CIK 0001724521 #1577 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$14.41M

$12.57M on a plan · $1.84M straight out of an exercise

Sold at will

$0.00

0 of 45 sales

Net

−$14.41M

$0.00 against sales at will

By person

16 insiders · 46 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Jaen Juan C.

President

—

$9.22M (21) scheduled

−$9.22M

1,199,252

0.9418%

$35.98M

−21.2%

Jarrett Jennifer

Chief Operating Officer

—

$2.17M (5) scheduled

−$2.17M

224,024

0.1759%

$6.72M

+16.8%

ROSEN TERRY J

Chief Executive Officer

—

$1.20M (2) scheduled

−$1.20M

2,236,409

1.76%

$67.09M

+6.4%

Goeltz II Robert C.

Chief Financial Officer

—

$855.89K (6) scheduled

−$855.89K

84,161

0.0661%

$2.52M

+14.0%

Azoy Alexander

Chief Accounting Officer

—

$432.47K (7) scheduled

−$432.47K

39,581

0.0311%

$1.19M

+69.1%

Tang Carolyn C.

General Counsel

—

$318.50K (2) scheduled

−$318.50K

184,607

0.1450%

$5.54M

+60.1%

Markus Richard

Chief Medical Officer

—

$210.14K (2) scheduled

−$210.14K

89,647

0.0704%

$2.69M

—

GILEAD SCIENCES, INC. entity

10% owner

—

31,424,760

24.68%

$942.74M

+4.5%

Nuyten Dimitry SA

Chief Medical Officer

—

87,518

0.0687%

$2.63M

−8.2%

Lacey David L.

Director

—

76,652

0.0602%

$2.30M

+33.0%

PERLMAN ANDREW J

Director

—

48,325

0.0380%

$1.45M

+64.8%

FALBERG KATHRYN E

Director

—

44,300

0.0348%

$1.33M

+75.1%

Machado Patrick

Director

—

44,300

0.0348%

$1.33M

+75.1%

Ribas Antoni

Director

—

44,300

0.0348%

$1.33M

+46.0%

Lambert Nicole

Director

—

43,000

0.0338%

$1.29M

+79.2%

KANEKO YASUNORI

Director

—

25,700

0.0202%

$771.00K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Tang Carolyn C.

11 Jun 2026

General Counsel

Exercised, kept

34,090

$2.57

$87.75K

Show all 46 transactions →

What was left out

Form 4 filings counted 42

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 40

Sales straight out of an exercise 5

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 455,800

History held since 19 Mar 2018